A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...